热门资讯> 正文
Viking Therapeutics每股收益未达标导致股价下跌7%
2025-07-24 05:51
- Viking Therapeutics (NASDAQ:VKTX) is down ~7% in after-hours trading Wednesday after its Q2 bottom line results missed the mark. The company did not report any revenue.
- The biotech saw its net loss widen to ($0.58) from ($0.20) in the year-ago period.
- Viking was hurt in the quarter by a ~119% increase in total operating costs to ~$74.6M.
- The company ended the quarter (June 30) with cash and cash equivalents of ~$33.9M compared to ~$26.7M on Dec. 31, 2024.
More on Viking Therapeutics
- Viking Therapeutics: What's Next After GLP-1 Hype Dies Down And Competition Intensifies
- Viking: I'm Bullish On Oral/Injectable GLP-1 Obesity Data Catalysts
- Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential
- Viking Therapeutics GAAP EPS of -$0.58 misses by $0.12
- Madrigal, Viking among notable gainers after Altimmune’s MASH setback
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
